pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MLTXMoonLake Immunotherapeutics

$MLTX11.53+6.76%
Zug, CHupdated 9d ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
sonelokimab
Psoriatic Arthritis
Interleukin-17AInterleukin-17F

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Responseactive not recruitingn=600
  • phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritisenrolling by invitationn=1,560
  • phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drugactive not recruitingn=960
  • phase3Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativacompletedn=418
  • phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativaenrolling by invitationn=835
  • phase3An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)recruitingn=35
  • phase1An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjectorcompletedn=120
  • phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativaactive not recruitingn=422
🐶 Hiring Signal
No open roles indexed yet — view MoonLake Immunotherapeutics jobs →

News

  • STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
    German researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment. Now he's co-founding his own company.
    stat · 3mo ago
  • STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
    A newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series of patient deaths, experts say.
    stat · 3mo ago
  • STAT+: Trump is counting on the health care industry to remake vaccines. It’s pushing back instead
    Trump wants to change how American kids are vaccinated, but doctors and the pharma industry aren't on board.
    stat · 3mo ago
  • STAT+: Skylark Bio kicks off new gene therapy trial for deafness
    Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.
    stat · 3mo ago
  • IRBs have a problem. Can North Star’s nonprofit model save it?
    As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.
    stat · 3mo ago
  • STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
    Biotech companies don’t hide or obfuscate strong data.
    stat · 3mo ago
  • STAT+: Nurses seek a seat at the table as they fight expanding clinical AI
    Nurses, who make up the largest part of the health care workforce, say clinical artificial intelligence poses a threat to their jobs, and patients.
    stat · 3mo ago
  • MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
    MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
    fiercebiotech · 3mo ago
  • Avalo shares spike on skin drug data; BioNTech to cut staff
    Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
    biopharma_dive · 6mo ago
view all news mentions →
identifiers
ticker
$MLTX
SEC CIK
0001821586
country
CH
source
sec_tickers
top tags
Dermatology1Immunology1
mentioned in
9news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?